FDA Accepts Dacogen sNDA Submission in Acute Myeloid Leukemia

SuperGen announced that Eisai released information that the FDA has accepted for review its supplemental New Drug Application (sNDA) seeking approval of Dacogen (decitabine) for injection in the treatment of acute myeloid leukemia.
MarketWatch